Samsung Biologics completes pilot production of mRNA vaccine substance

2022.08.03 13:35:20

[Source: Samsung Biologics Co.]이미지 확대

[Source: Samsung Biologics Co.]

Samsung Biologics has completed its first pilot production run for mRNA vaccine substance, achieving another feat after its successful contract manufacturing for Moderna’s finished mRNA coronavirus vaccine. In November last year, the Korean CMO giant signed an agreement to manufacture vaccine substance for GreenLight Biosciences, another U.S. Covid jab developer.

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]

MOST READ MOST RECENT
  1. 1Global tech companies declare OS war
  2. 2Samsung’s Galaxy Watch7 to have blood sugar monitoring feature
  3. 3KB Financial Group rakes in $750 mn in Q1 net profit
  4. 4Korea’s secondary battery stocks slide amid sluggish EV demand
  5. 5Hyundai Motor achieves record Q1 sales on strong high-end vehicle dema..
  1. 1Musinsa’s Starfield Suwon store draws crowds
  2. 2HMM to implement AI video analysis solution to enhance ship safety
  3. 3MedySapiens initiates global expansion with deals in Taiwan
  4. 4SK on to be successful with its IPO: Executive
  5. 5Lotte to pull out of China
  6. 6Jeju Air drops Asiana cargo business sale bid